• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

I期和III期非小细胞肺癌（NSCLC）患者潜在的预后和预测性免疫生物标志物的鉴定：一项前瞻性探索性研究。

Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study.

作者信息

Vaes Rianne D W, Reynders Kobe, Sprooten Jenny, Nevola Kathleen T, Rouschop Kasper M A, Vooijs Marc, Garg Abhishek D, Lambrecht Maarten, Hendriks Lizza E L, Rucevic Marijana, De Ruysscher Dirk

机构信息

Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.

Cell Stress & Immunity (CSI) Lab, Department for Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.

出版信息

Cancers (Basel). 2021 Dec 13;13(24):6259. doi: 10.3390/cancers13246259.

DOI:10.3390/cancers13246259
PMID:34944879
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8699057/
Abstract

Radiotherapy (RT) and chemotherapy can induce immune responses, but not much is known regarding treatment-induced immune changes in patients. This exploratory study aimed to identify potential prognostic and predictive immune-related proteins associated with progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC). In this prospective study, patients with stage I NSCLC treated with stereotactic body radiation therapy ( = 26) and patients with stage III NSCLC treated with concurrent chemoradiotherapy ( = 18) were included. Blood samples were collected before (v1), during (v2), and after RT (v3). In patients with stage I NSCLC, CD244 (HR: 10.2, 95% CI: 1.8-57.4) was identified as a negative prognostic biomarker. In patients with stage III NSCLC, CR2 and IFNGR2 were identified as positive prognostic biomarkers (CR2, HR: 0.00, 95% CI: 0.00-0.12; IFNGR2, HR: 0.04, 95% CI: 0.00-0.46). In addition, analysis of the treatment-induced changes of circulating protein levels over time (Δv2/v3-v1) also identified CXCL10 and IL-10 as negative predictive biomarkers (CXCL10, HR: 3.86, 95% CI: 1.0-14.7; IL-10, HR: 16.92 (2.74-104.36)), although serum-induced interferon (IFN) response was a positive prognostic. In conclusion, we identified several circulating immunogenic proteins that are correlated with PFS in patients with stage I and stage III NSCLC before and during treatment.

摘要

放射疗法（RT）和化疗可诱导免疫反应，但对于治疗引起的患者免疫变化知之甚少。这项探索性研究旨在确定与非小细胞肺癌（NSCLC）患者无进展生存期（PFS）相关的潜在预后和预测性免疫相关蛋白。在这项前瞻性研究中，纳入了接受立体定向体部放射治疗的I期NSCLC患者（n = 26）和接受同步放化疗的III期NSCLC患者（n = 18）。在放疗前（v1）、放疗期间（v2）和放疗后（v3）采集血样。在I期NSCLC患者中，CD244（HR：10.2，95%CI：1.8 - 57.4）被确定为负性预后生物标志物。在III期NSCLC患者中，CR2和IFNGR2被确定为正性预后生物标志物（CR2，HR：0.00，95%CI：0.00 - 0.12；IFNGR2，HR：0.04，95%CI：0.00 - 0.46）。此外，对循环蛋白水平随时间的治疗诱导变化（Δv2/v3 - v1）的分析还确定CXCL10和IL - 10为负性预测生物标志物（CXCL10，HR：3.86，95%CI：1.0 - 14.7；IL - 10，HR：16.92（2.74 - 104.36）），尽管血清诱导的干扰素（IFN）反应是正性预后因素。总之，我们确定了几种循环免疫原性蛋白，它们在I期和III期NSCLC患者治疗前和治疗期间与PFS相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cef/8699057/206e77a72449/cancers-13-06259-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cef/8699057/b4a4877eb329/cancers-13-06259-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cef/8699057/0b8169f49651/cancers-13-06259-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cef/8699057/f670c5526a4d/cancers-13-06259-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cef/8699057/c47f4ed0df76/cancers-13-06259-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cef/8699057/206e77a72449/cancers-13-06259-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cef/8699057/b4a4877eb329/cancers-13-06259-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cef/8699057/0b8169f49651/cancers-13-06259-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cef/8699057/f670c5526a4d/cancers-13-06259-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cef/8699057/c47f4ed0df76/cancers-13-06259-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cef/8699057/206e77a72449/cancers-13-06259-g005.jpg

相似文献

1
Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study.I期和III期非小细胞肺癌（NSCLC）患者潜在的预后和预测性免疫生物标志物的鉴定：一项前瞻性探索性研究。
Cancers (Basel). 2021 Dec 13;13(24):6259. doi: 10.3390/cancers13246259.
2
Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.治疗前预后营养指数作为一种新型生物标志物在接受免疫检查点抑制剂治疗的非小细胞肺癌患者中的应用。
Lung Cancer. 2019 Oct;136:45-51. doi: 10.1016/j.lungcan.2019.08.006. Epub 2019 Aug 14.
3
Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer.中性粒细胞增多作为局部晚期 III 期肺癌的预后生物标志物。
PLoS One. 2018 Oct 10;13(10):e0204490. doi: 10.1371/journal.pone.0204490. eCollection 2018.
4
The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值在接受同步放化疗的Ⅲ期非小细胞肺癌患者中的预后作用
Indian J Cancer. 2018 Jul-Sep;55(3):276-281. doi: 10.4103/ijc.IJC_624_17.
5
Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.空腹血糖是同期放化疗治疗局部晚期非小细胞肺癌患者生存的独立预测因子。
BMC Cancer. 2019 Feb 21;19(1):165. doi: 10.1186/s12885-019-5370-5.
6
Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.尿激酶型纤溶酶原激活物系统和骨桥蛋白在接受放疗的非小细胞肺癌患者中的共同检测对预后的影响及其与大体肿瘤体积的相关性。
Strahlenther Onkol. 2018 Jun;194(6):539-551. doi: 10.1007/s00066-017-1255-1. Epub 2018 Jan 16.
7
Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.接受根治性同步放化疗的Ⅲ期非小细胞肺癌患者中，淋巴结标准化摄取值对生存的预后意义
Am J Clin Oncol. 2016 Aug;39(4):355-62. doi: 10.1097/COC.0000000000000070.
8
Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.在接受同步放化疗的 III 期非小细胞肺癌患者中，PD-L1 表达与 CD8 + 肿瘤浸润淋巴细胞密度联合的预测相关性
Eur J Cancer. 2016 Mar;55:7-14. doi: 10.1016/j.ejca.2015.11.020. Epub 2016 Jan 6.
9
Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.系统免疫炎症指数预测 III 期非小细胞肺癌患者的放化疗耐药和不良预后。
J Transl Med. 2017 Oct 31;15(1):221. doi: 10.1186/s12967-017-1326-1.
10
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.与接受放化疗后巩固性派姆单抗治疗的 III 期 NSCLC 患者的改善预后相关的预测变量：印第安纳癌症研究网络 LUN 14-179 二期研究的亚组分析。
Clin Lung Cancer. 2020 May;21(3):288-293. doi: 10.1016/j.cllc.2019.06.009. Epub 2019 Jul 8.

引用本文的文献

1
Induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy for unresectable stage III non-small cell lung cancer: a multi-institutional retrospective cohort study.诱导免疫化疗联合根治性放化疗及巩固免疫治疗用于不可切除的Ⅲ期非小细胞肺癌：一项多机构回顾性队列研究
Front Immunol. 2025 Jul 31;16:1602082. doi: 10.3389/fimmu.2025.1602082. eCollection 2025.
2
The prognostic and predictive value of peripheral immune-related proteins in patients with lung cancer treated with radiotherapy.外周免疫相关蛋白在接受放疗的肺癌患者中的预后及预测价值
Front Oncol. 2025 Jul 17;15:1625212. doi: 10.3389/fonc.2025.1625212. eCollection 2025.
3

本文引用的文献

1
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.外周驱动的髓系 NFkB 和 IFN/ISG 反应可预测卵巢癌的恶性风险、生存和免疫治疗方案。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003609.
2
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.IMpower150 研究中阿替利珠单抗联合贝伐珠单抗和化疗一线治疗转移性非鳞状 NSCLC 的最终总生存分析。
J Thorac Oncol. 2021 Nov;16(11):1909-1924. doi: 10.1016/j.jtho.2021.07.009. Epub 2021 Jul 24.
3
Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10.
STRONG II trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma - a single-arm multicentre phase II study.
STRONG II试验：不可切除的肝门部胆管癌化疗后立体定向体部放射治疗——一项单臂多中心II期研究。
BMJ Open. 2025 Jul 16;15(7):e097545. doi: 10.1136/bmjopen-2024-097545.
4
Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1/PD-L1 blockades in NSCLC: a prospective exploratory study.利用血浆蛋白质组学进行液体活检以预测非小细胞肺癌中PD-1/PD-L1阻断疗法的疗效和耐受性：一项前瞻性探索性研究。
Mol Biomed. 2025 Jul 15;6(1):51. doi: 10.1186/s43556-025-00291-6.
5
A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC.不可切除Ⅲ期非小细胞肺癌治疗中免疫调节的批判性综述
Cancers (Basel). 2025 May 30;17(11):1829. doi: 10.3390/cancers17111829.
6
The BNT162b2 mRNA vaccine demonstrates reduced age-associated T1 support and .BNT162b2信使核糖核酸疫苗显示出与年龄相关的T1支持减少，以及……（原文此处不完整）
iScience. 2024 Sep 26;27(11):111055. doi: 10.1016/j.isci.2024.111055. eCollection 2024 Nov 15.
7
Prognostic value of circulating proteins at diagnosis among patients with lung cancer: a comprehensive analysis by smoking status.肺癌患者诊断时循环蛋白的预后价值：基于吸烟状态的综合分析
Transl Lung Cancer Res. 2024 Sep 30;13(9):2326-2339. doi: 10.21037/tlcr-24-242. Epub 2024 Sep 27.
8
Trial watch: anticancer vaccination with dendritic cells.试验观察：树突状细胞抗癌疫苗。
Oncoimmunology. 2024 Oct 9;13(1):2412876. doi: 10.1080/2162402X.2024.2412876. eCollection 2024.
9
Identifying potential therapeutic targets in lung adenocarcinoma: a multi-omics approach integrating bulk and single-cell RNA sequencing with Mendelian randomization.鉴定肺腺癌中的潜在治疗靶点：一种整合批量和单细胞RNA测序与孟德尔随机化的多组学方法。
Front Pharmacol. 2024 Jul 18;15:1433147. doi: 10.3389/fphar.2024.1433147. eCollection 2024.
10
Distinct roles of CD244 expression in cancer diagnosis and prognosis: A pan-cancer analysis.CD244表达在癌症诊断和预后中的不同作用：一项泛癌分析。
Heliyon. 2024 Mar 30;10(7):e28928. doi: 10.1016/j.heliyon.2024.e28928. eCollection 2024 Apr 15.
错配修复缺陷型结直肠癌中的抗肿瘤免疫需要 I 型 IFN 驱动的 CCL5 和 CXCL10。
J Exp Med. 2021 Sep 6;218(9). doi: 10.1084/jem.20210108. Epub 2021 Jul 23.
4
Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer.晚期肺癌患者全身抗癌治疗期间血浆中损伤相关分子模式水平升高。
Transl Lung Cancer Res. 2021 Jun;10(6):2475-2486. doi: 10.21037/tlcr-21-92.
5
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC.IMpower110 研究中更新的总生存分析：阿替利珠单抗对比化疗治疗 PD-L1 选择的初治 NSCLC。
J Thorac Oncol. 2021 Nov;16(11):1872-1882. doi: 10.1016/j.jtho.2021.06.019. Epub 2021 Jul 12.
6
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.KEYNOTE-010 研究：帕博利珠单抗对比多西他赛用于治疗既往接受过治疗、PD-L1 阳性的晚期 NSCLC 的 5 年生存更新。
J Thorac Oncol. 2021 Oct;16(10):1718-1732. doi: 10.1016/j.jtho.2021.05.001. Epub 2021 May 26.
7
Biomarkers of Radiotherapy-Induced Immunogenic Cell Death.放疗诱导免疫原性细胞死亡的生物标志物。
Cells. 2021 Apr 17;10(4):930. doi: 10.3390/cells10040930.
8
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.培美曲塞联合铂类与或不联合帕博利珠单抗治疗未经治疗的转移性非鳞状非小细胞肺癌患者：KEYNOTE-189 的方案预设的最终分析。
Ann Oncol. 2021 Jul;32(7):881-895. doi: 10.1016/j.annonc.2021.04.008. Epub 2021 Apr 22.
9
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.帕博利珠单抗对比化疗用于 PD-L1 肿瘤比例分数≥50%的转移性非小细胞肺癌的 5 年结果。
J Clin Oncol. 2021 Jul 20;39(21):2339-2349. doi: 10.1200/JCO.21.00174. Epub 2021 Apr 19.
10
Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands.2008年至2018年I-III期非小细胞肺癌治疗的趋势与变化：一项来自荷兰的全国性基于人群的研究。
Lung Cancer. 2021 May;155:103-113. doi: 10.1016/j.lungcan.2021.03.013. Epub 2021 Mar 20.